Skip to main content
. 2020 Nov 2;20(14):1–148.

Table A3:

NYHA Functional Class

Author, Year N (TAVI/SAVR) Baseline 30 Days 1 Year
Mack et al, 201918
950 (496/454)

PARTNER 3		 N = 950 (496 TAVI/454 SAVR)

NYHA I, n (%)
TAVI: 2 (0.4)
SAVR: 7 (1.5)

NYHA II, n (%)
TAVI: 339 (68.3)
SAVR: 339 (74.7)

NYHA III, n (%)
TAVI: 152 (30.6)
SAVR: 103 (22.7)

NYHA IV, n (%)
TAVI: 3 (0.6)
SAVR: 5 (1.1)		 N = 926 (493 TAVI/433 SAVR)

NYHA I, n (%)
TAVI: 396 (80.3)
SAVR: 289 (66.7)

RD, % (95% CI)
−13.4 (−19.2 to −7.9)

NYHA II, n (%)
TAVI: 339 (68.3)
SAVR: 339 (74.7)

NYHA III, n (%)
TAVI: 91 (18.5)
SAVR: 125 (28.9)

NYHA IV, n (%)
TAVI: 6 (1.2)
SAVR: 19 (44)		 N = 887 (480 TAVI/407 SAVR)

NYHA I, n (%)
TAVI: 395 (82.3)
SAVR: 339 (83.3)

RD, % (95% CI)
1.0 (−4.0 to 6.0)

NYHA II, n (%)
TAVI: 339 (16.7)
SAVR: 339 (74.7)

NYHA III, n (%)
TAVI: 80 (16.7)
SAVR: 62 (15.2)

NYHA IV, n (%)
TAVI: 5 (1.0)
SAVR: 6 (1.5)
Popma et al, 2019
1,403 (725/678)

Evolut LRT		 N = 1,403 (725 TAVI/678 SAVR)

NYHA I, n (%)
AVI: 76 (10.5)
SAVR: 63 (9.3)

NYHA II, n (%)
TAVI: 467 (64.4)
SAVR: 422 (62.2)

NYHA III, n (%)
TAVI: 181 (25.0)
SAVR: 190 (28.0)

NYHA IV, n (%)
TAVI: 1 (0.1)
SAVR: 3 (0.4)		 N = 1,331 (706 TAVI/625 SAVR)

NYHA I, n (%)
TAVI: 545 (77.2)
SAVR: 416 (66.6)

NYHA II, n (%)
TAVI: 149 (21.1)
SAVR: 179 (28.6)

NYHA III, n (%)
TAVI: 12 (1.7)
SAVR: 29 (4.6)

NYHA IV, n (%)
TAVI: 0
SAVR: 1 (0.2)		 N = 770 (428 TAVI/342 SAVR)

Mean change from baseline (SD)
TAVI: 0.9 (0.7)
SAVR: 1.0 (0.7)

Mean difference (95% BCrI)
−0.1 (−0.2 to 0.0)

NYHA I, n (%)
TAVI: 336 (78.5)
SAVR: 279 (81.6)

NYHA II, n (%)
TAVI: 84 (19.6)
SAVR: 59 (17.3)

NYHA III, n (%)
TAVI: 7 (1.6)
SAVR: 4 (1.2)

NYHA IV, n (%)
TAVI: 1 (0.2)
SAVR: 0

Abbreviations: BCrI, Bayesian credible interval; NYHA, New York Heart Association; RD, risk difference; SAVR, surgical aortic valve replacement; SD, standard deviation; TAVI, transcatheter aortic valve implantation.